CANCER RES 润色咨询

CANCER RESEARCH

出版年份:1941 年文章数:12632 投稿命中率: 开通期刊会员,数据随心看

出版周期:Semimonthly 自引率:2.6% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2139835, encodeId=0ab721398353a, content=偏重的研究方向:肿瘤基础研究;肿瘤<br>经验分享:审稿好慢,under editorial consideration已经五天了,这是编辑还没看吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ca15460308, createdName=ms3000001338909804, createdTime=Tue May 30 07:52:31 CST 2023, time=2023-05-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2175276, encodeId=4dec21e5276a4, content=这个期刊的under review是内审还是外审呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8332469177, createdName=12433741m11(暂无昵称), createdTime=Sat Dec 16 14:20:32 CST 2023, time=2023-12-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2158905, encodeId=9aff2158905d4, content=各位大佬们,这个杂志under editorial consideration 大概需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Thu Sep 21 14:00:28 CST 2023, time=2023-09-21, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2096624, encodeId=816c2096624f0, content=请问下大家提交后状态一直是live manuscripts代表什么呀?感觉跟大家的状态不一样呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee235490897, createdName=嘻嘻哈哈623, createdTime=Fri Oct 28 09:46:16 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147875, encodeId=5c0f214e8751c, content=请问下大家,文章proof回去之后多久能更新啊?网站上一直都还是之前我们提交的pre-proof版本, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:30:27 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2147876, encodeId=9bf2214e8765b, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:蛋白质翻译后修饰;肿瘤<br>经验分享:请问大家proof结束后多久能有排好版的文章上线啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:32:28 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2145679, encodeId=996121456e992, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤<br>经验分享:投过三次,送外审会通知你。<br>第一次外审1个月,三个审稿人,意见都不乐观,被拒。改投oncogene,中。<br>第二次外审1个月,三个审稿意见,一个乐观,2个中性,大修后接受,从投稿到接受用了4个月。<br>第三次,合作文章,并列作者,秒拒。<br>编辑的态度不错,回复问题很及时。投稿系统bug非常多!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd8b8736567, createdName=ms4000000933785288, createdTime=Fri Jun 30 16:32:39 CST 2023, time=2023-06-30, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2109990, encodeId=f6a9210999082, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤研究<br>经验分享:比较难搞,第一稿<br>Stage Start Date<br>Revision Received 2022-07-15 09:55:14<br>Waiting for Revision 2022-01-18 09:15:09<br>Decision Sent to Author 2022-01-18 09:15:09<br>Decision Pending 2022-01-18 07:43:20<br>Under Review 2021-12-15 16:40:12<br>Under Editorial Consideration 2021-12-15 10:25:39<br>Initial QC 2021-12-13 07:05:17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=482d4748397, createdName=hhhhhccc, createdTime=Thu Jan 12 20:15:37 CST 2023, time=2023-01-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2143534, encodeId=d49d21435346b, content=审稿速度:1.0<br>偏重的研究方向:肿瘤<br>经验分享:因为格式问题让修改,修改后又提交了,然后就停在Initial QC 2天了,这样不会被忘记吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Sun Jun 18 21:16:54 CST 2023, time=2023-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2128280, encodeId=dbfb212828078, content=请问这个杂质接收以后需要提交原始数据吗?提交什么格式的原始数据呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5e1735331, createdName=爱的橙子蓝, createdTime=Tue Apr 25 18:42:56 CST 2023, time=2023-04-25, status=1, ipAttribution=天津)]
    2023-05-30 ms3000001338909804 来自湖北省

    偏重的研究方向:肿瘤基础研究;肿瘤
    经验分享:审稿好慢,under editorial consideration已经五天了,这是编辑还没看吗?

    5

    展开5条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2139835, encodeId=0ab721398353a, content=偏重的研究方向:肿瘤基础研究;肿瘤<br>经验分享:审稿好慢,under editorial consideration已经五天了,这是编辑还没看吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ca15460308, createdName=ms3000001338909804, createdTime=Tue May 30 07:52:31 CST 2023, time=2023-05-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2175276, encodeId=4dec21e5276a4, content=这个期刊的under review是内审还是外审呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8332469177, createdName=12433741m11(暂无昵称), createdTime=Sat Dec 16 14:20:32 CST 2023, time=2023-12-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2158905, encodeId=9aff2158905d4, content=各位大佬们,这个杂志under editorial consideration 大概需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Thu Sep 21 14:00:28 CST 2023, time=2023-09-21, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2096624, encodeId=816c2096624f0, content=请问下大家提交后状态一直是live manuscripts代表什么呀?感觉跟大家的状态不一样呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee235490897, createdName=嘻嘻哈哈623, createdTime=Fri Oct 28 09:46:16 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147875, encodeId=5c0f214e8751c, content=请问下大家,文章proof回去之后多久能更新啊?网站上一直都还是之前我们提交的pre-proof版本, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:30:27 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2147876, encodeId=9bf2214e8765b, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:蛋白质翻译后修饰;肿瘤<br>经验分享:请问大家proof结束后多久能有排好版的文章上线啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:32:28 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2145679, encodeId=996121456e992, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤<br>经验分享:投过三次,送外审会通知你。<br>第一次外审1个月,三个审稿人,意见都不乐观,被拒。改投oncogene,中。<br>第二次外审1个月,三个审稿意见,一个乐观,2个中性,大修后接受,从投稿到接受用了4个月。<br>第三次,合作文章,并列作者,秒拒。<br>编辑的态度不错,回复问题很及时。投稿系统bug非常多!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd8b8736567, createdName=ms4000000933785288, createdTime=Fri Jun 30 16:32:39 CST 2023, time=2023-06-30, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2109990, encodeId=f6a9210999082, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤研究<br>经验分享:比较难搞,第一稿<br>Stage Start Date<br>Revision Received 2022-07-15 09:55:14<br>Waiting for Revision 2022-01-18 09:15:09<br>Decision Sent to Author 2022-01-18 09:15:09<br>Decision Pending 2022-01-18 07:43:20<br>Under Review 2021-12-15 16:40:12<br>Under Editorial Consideration 2021-12-15 10:25:39<br>Initial QC 2021-12-13 07:05:17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=482d4748397, createdName=hhhhhccc, createdTime=Thu Jan 12 20:15:37 CST 2023, time=2023-01-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2143534, encodeId=d49d21435346b, content=审稿速度:1.0<br>偏重的研究方向:肿瘤<br>经验分享:因为格式问题让修改,修改后又提交了,然后就停在Initial QC 2天了,这样不会被忘记吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Sun Jun 18 21:16:54 CST 2023, time=2023-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2128280, encodeId=dbfb212828078, content=请问这个杂质接收以后需要提交原始数据吗?提交什么格式的原始数据呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5e1735331, createdName=爱的橙子蓝, createdTime=Tue Apr 25 18:42:56 CST 2023, time=2023-04-25, status=1, ipAttribution=天津)]
    2023-12-16 12433741m11(暂无昵称) 来自湖北省

    这个期刊的under review是内审还是外审呀?

    2

    展开2条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2139835, encodeId=0ab721398353a, content=偏重的研究方向:肿瘤基础研究;肿瘤<br>经验分享:审稿好慢,under editorial consideration已经五天了,这是编辑还没看吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ca15460308, createdName=ms3000001338909804, createdTime=Tue May 30 07:52:31 CST 2023, time=2023-05-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2175276, encodeId=4dec21e5276a4, content=这个期刊的under review是内审还是外审呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8332469177, createdName=12433741m11(暂无昵称), createdTime=Sat Dec 16 14:20:32 CST 2023, time=2023-12-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2158905, encodeId=9aff2158905d4, content=各位大佬们,这个杂志under editorial consideration 大概需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Thu Sep 21 14:00:28 CST 2023, time=2023-09-21, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2096624, encodeId=816c2096624f0, content=请问下大家提交后状态一直是live manuscripts代表什么呀?感觉跟大家的状态不一样呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee235490897, createdName=嘻嘻哈哈623, createdTime=Fri Oct 28 09:46:16 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147875, encodeId=5c0f214e8751c, content=请问下大家,文章proof回去之后多久能更新啊?网站上一直都还是之前我们提交的pre-proof版本, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:30:27 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2147876, encodeId=9bf2214e8765b, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:蛋白质翻译后修饰;肿瘤<br>经验分享:请问大家proof结束后多久能有排好版的文章上线啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:32:28 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2145679, encodeId=996121456e992, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤<br>经验分享:投过三次,送外审会通知你。<br>第一次外审1个月,三个审稿人,意见都不乐观,被拒。改投oncogene,中。<br>第二次外审1个月,三个审稿意见,一个乐观,2个中性,大修后接受,从投稿到接受用了4个月。<br>第三次,合作文章,并列作者,秒拒。<br>编辑的态度不错,回复问题很及时。投稿系统bug非常多!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd8b8736567, createdName=ms4000000933785288, createdTime=Fri Jun 30 16:32:39 CST 2023, time=2023-06-30, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2109990, encodeId=f6a9210999082, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤研究<br>经验分享:比较难搞,第一稿<br>Stage Start Date<br>Revision Received 2022-07-15 09:55:14<br>Waiting for Revision 2022-01-18 09:15:09<br>Decision Sent to Author 2022-01-18 09:15:09<br>Decision Pending 2022-01-18 07:43:20<br>Under Review 2021-12-15 16:40:12<br>Under Editorial Consideration 2021-12-15 10:25:39<br>Initial QC 2021-12-13 07:05:17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=482d4748397, createdName=hhhhhccc, createdTime=Thu Jan 12 20:15:37 CST 2023, time=2023-01-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2143534, encodeId=d49d21435346b, content=审稿速度:1.0<br>偏重的研究方向:肿瘤<br>经验分享:因为格式问题让修改,修改后又提交了,然后就停在Initial QC 2天了,这样不会被忘记吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Sun Jun 18 21:16:54 CST 2023, time=2023-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2128280, encodeId=dbfb212828078, content=请问这个杂质接收以后需要提交原始数据吗?提交什么格式的原始数据呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5e1735331, createdName=爱的橙子蓝, createdTime=Tue Apr 25 18:42:56 CST 2023, time=2023-04-25, status=1, ipAttribution=天津)]
    2023-09-21 ms1000000959787142 来自天津

    各位大佬们,这个杂志under editorial consideration 大概需要多久呀

    5

    展开5条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2139835, encodeId=0ab721398353a, content=偏重的研究方向:肿瘤基础研究;肿瘤<br>经验分享:审稿好慢,under editorial consideration已经五天了,这是编辑还没看吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ca15460308, createdName=ms3000001338909804, createdTime=Tue May 30 07:52:31 CST 2023, time=2023-05-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2175276, encodeId=4dec21e5276a4, content=这个期刊的under review是内审还是外审呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8332469177, createdName=12433741m11(暂无昵称), createdTime=Sat Dec 16 14:20:32 CST 2023, time=2023-12-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2158905, encodeId=9aff2158905d4, content=各位大佬们,这个杂志under editorial consideration 大概需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Thu Sep 21 14:00:28 CST 2023, time=2023-09-21, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2096624, encodeId=816c2096624f0, content=请问下大家提交后状态一直是live manuscripts代表什么呀?感觉跟大家的状态不一样呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee235490897, createdName=嘻嘻哈哈623, createdTime=Fri Oct 28 09:46:16 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147875, encodeId=5c0f214e8751c, content=请问下大家,文章proof回去之后多久能更新啊?网站上一直都还是之前我们提交的pre-proof版本, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:30:27 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2147876, encodeId=9bf2214e8765b, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:蛋白质翻译后修饰;肿瘤<br>经验分享:请问大家proof结束后多久能有排好版的文章上线啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:32:28 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2145679, encodeId=996121456e992, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤<br>经验分享:投过三次,送外审会通知你。<br>第一次外审1个月,三个审稿人,意见都不乐观,被拒。改投oncogene,中。<br>第二次外审1个月,三个审稿意见,一个乐观,2个中性,大修后接受,从投稿到接受用了4个月。<br>第三次,合作文章,并列作者,秒拒。<br>编辑的态度不错,回复问题很及时。投稿系统bug非常多!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd8b8736567, createdName=ms4000000933785288, createdTime=Fri Jun 30 16:32:39 CST 2023, time=2023-06-30, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2109990, encodeId=f6a9210999082, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤研究<br>经验分享:比较难搞,第一稿<br>Stage Start Date<br>Revision Received 2022-07-15 09:55:14<br>Waiting for Revision 2022-01-18 09:15:09<br>Decision Sent to Author 2022-01-18 09:15:09<br>Decision Pending 2022-01-18 07:43:20<br>Under Review 2021-12-15 16:40:12<br>Under Editorial Consideration 2021-12-15 10:25:39<br>Initial QC 2021-12-13 07:05:17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=482d4748397, createdName=hhhhhccc, createdTime=Thu Jan 12 20:15:37 CST 2023, time=2023-01-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2143534, encodeId=d49d21435346b, content=审稿速度:1.0<br>偏重的研究方向:肿瘤<br>经验分享:因为格式问题让修改,修改后又提交了,然后就停在Initial QC 2天了,这样不会被忘记吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Sun Jun 18 21:16:54 CST 2023, time=2023-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2128280, encodeId=dbfb212828078, content=请问这个杂质接收以后需要提交原始数据吗?提交什么格式的原始数据呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5e1735331, createdName=爱的橙子蓝, createdTime=Tue Apr 25 18:42:56 CST 2023, time=2023-04-25, status=1, ipAttribution=天津)]
    2022-10-28 嘻嘻哈哈623

    请问下大家提交后状态一直是live manuscripts代表什么呀?感觉跟大家的状态不一样呀

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2139835, encodeId=0ab721398353a, content=偏重的研究方向:肿瘤基础研究;肿瘤<br>经验分享:审稿好慢,under editorial consideration已经五天了,这是编辑还没看吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ca15460308, createdName=ms3000001338909804, createdTime=Tue May 30 07:52:31 CST 2023, time=2023-05-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2175276, encodeId=4dec21e5276a4, content=这个期刊的under review是内审还是外审呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8332469177, createdName=12433741m11(暂无昵称), createdTime=Sat Dec 16 14:20:32 CST 2023, time=2023-12-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2158905, encodeId=9aff2158905d4, content=各位大佬们,这个杂志under editorial consideration 大概需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Thu Sep 21 14:00:28 CST 2023, time=2023-09-21, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2096624, encodeId=816c2096624f0, content=请问下大家提交后状态一直是live manuscripts代表什么呀?感觉跟大家的状态不一样呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee235490897, createdName=嘻嘻哈哈623, createdTime=Fri Oct 28 09:46:16 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147875, encodeId=5c0f214e8751c, content=请问下大家,文章proof回去之后多久能更新啊?网站上一直都还是之前我们提交的pre-proof版本, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:30:27 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2147876, encodeId=9bf2214e8765b, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:蛋白质翻译后修饰;肿瘤<br>经验分享:请问大家proof结束后多久能有排好版的文章上线啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:32:28 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2145679, encodeId=996121456e992, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤<br>经验分享:投过三次,送外审会通知你。<br>第一次外审1个月,三个审稿人,意见都不乐观,被拒。改投oncogene,中。<br>第二次外审1个月,三个审稿意见,一个乐观,2个中性,大修后接受,从投稿到接受用了4个月。<br>第三次,合作文章,并列作者,秒拒。<br>编辑的态度不错,回复问题很及时。投稿系统bug非常多!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd8b8736567, createdName=ms4000000933785288, createdTime=Fri Jun 30 16:32:39 CST 2023, time=2023-06-30, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2109990, encodeId=f6a9210999082, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤研究<br>经验分享:比较难搞,第一稿<br>Stage Start Date<br>Revision Received 2022-07-15 09:55:14<br>Waiting for Revision 2022-01-18 09:15:09<br>Decision Sent to Author 2022-01-18 09:15:09<br>Decision Pending 2022-01-18 07:43:20<br>Under Review 2021-12-15 16:40:12<br>Under Editorial Consideration 2021-12-15 10:25:39<br>Initial QC 2021-12-13 07:05:17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=482d4748397, createdName=hhhhhccc, createdTime=Thu Jan 12 20:15:37 CST 2023, time=2023-01-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2143534, encodeId=d49d21435346b, content=审稿速度:1.0<br>偏重的研究方向:肿瘤<br>经验分享:因为格式问题让修改,修改后又提交了,然后就停在Initial QC 2天了,这样不会被忘记吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Sun Jun 18 21:16:54 CST 2023, time=2023-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2128280, encodeId=dbfb212828078, content=请问这个杂质接收以后需要提交原始数据吗?提交什么格式的原始数据呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5e1735331, createdName=爱的橙子蓝, createdTime=Tue Apr 25 18:42:56 CST 2023, time=2023-04-25, status=1, ipAttribution=天津)]
    2023-07-13 ms9000000602781212 来自北京

    请问下大家,文章proof回去之后多久能更新啊?网站上一直都还是之前我们提交的pre-proof版本

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2139835, encodeId=0ab721398353a, content=偏重的研究方向:肿瘤基础研究;肿瘤<br>经验分享:审稿好慢,under editorial consideration已经五天了,这是编辑还没看吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ca15460308, createdName=ms3000001338909804, createdTime=Tue May 30 07:52:31 CST 2023, time=2023-05-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2175276, encodeId=4dec21e5276a4, content=这个期刊的under review是内审还是外审呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8332469177, createdName=12433741m11(暂无昵称), createdTime=Sat Dec 16 14:20:32 CST 2023, time=2023-12-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2158905, encodeId=9aff2158905d4, content=各位大佬们,这个杂志under editorial consideration 大概需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Thu Sep 21 14:00:28 CST 2023, time=2023-09-21, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2096624, encodeId=816c2096624f0, content=请问下大家提交后状态一直是live manuscripts代表什么呀?感觉跟大家的状态不一样呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee235490897, createdName=嘻嘻哈哈623, createdTime=Fri Oct 28 09:46:16 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147875, encodeId=5c0f214e8751c, content=请问下大家,文章proof回去之后多久能更新啊?网站上一直都还是之前我们提交的pre-proof版本, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:30:27 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2147876, encodeId=9bf2214e8765b, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:蛋白质翻译后修饰;肿瘤<br>经验分享:请问大家proof结束后多久能有排好版的文章上线啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:32:28 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2145679, encodeId=996121456e992, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤<br>经验分享:投过三次,送外审会通知你。<br>第一次外审1个月,三个审稿人,意见都不乐观,被拒。改投oncogene,中。<br>第二次外审1个月,三个审稿意见,一个乐观,2个中性,大修后接受,从投稿到接受用了4个月。<br>第三次,合作文章,并列作者,秒拒。<br>编辑的态度不错,回复问题很及时。投稿系统bug非常多!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd8b8736567, createdName=ms4000000933785288, createdTime=Fri Jun 30 16:32:39 CST 2023, time=2023-06-30, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2109990, encodeId=f6a9210999082, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤研究<br>经验分享:比较难搞,第一稿<br>Stage Start Date<br>Revision Received 2022-07-15 09:55:14<br>Waiting for Revision 2022-01-18 09:15:09<br>Decision Sent to Author 2022-01-18 09:15:09<br>Decision Pending 2022-01-18 07:43:20<br>Under Review 2021-12-15 16:40:12<br>Under Editorial Consideration 2021-12-15 10:25:39<br>Initial QC 2021-12-13 07:05:17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=482d4748397, createdName=hhhhhccc, createdTime=Thu Jan 12 20:15:37 CST 2023, time=2023-01-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2143534, encodeId=d49d21435346b, content=审稿速度:1.0<br>偏重的研究方向:肿瘤<br>经验分享:因为格式问题让修改,修改后又提交了,然后就停在Initial QC 2天了,这样不会被忘记吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Sun Jun 18 21:16:54 CST 2023, time=2023-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2128280, encodeId=dbfb212828078, content=请问这个杂质接收以后需要提交原始数据吗?提交什么格式的原始数据呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5e1735331, createdName=爱的橙子蓝, createdTime=Tue Apr 25 18:42:56 CST 2023, time=2023-04-25, status=1, ipAttribution=天津)]
    2023-07-13 ms9000000602781212 来自北京

    审稿速度:2.0 | 投稿命中率:25.0
    偏重的研究方向:蛋白质翻译后修饰;肿瘤
    经验分享:请问大家proof结束后多久能有排好版的文章上线啊?

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2139835, encodeId=0ab721398353a, content=偏重的研究方向:肿瘤基础研究;肿瘤<br>经验分享:审稿好慢,under editorial consideration已经五天了,这是编辑还没看吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ca15460308, createdName=ms3000001338909804, createdTime=Tue May 30 07:52:31 CST 2023, time=2023-05-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2175276, encodeId=4dec21e5276a4, content=这个期刊的under review是内审还是外审呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8332469177, createdName=12433741m11(暂无昵称), createdTime=Sat Dec 16 14:20:32 CST 2023, time=2023-12-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2158905, encodeId=9aff2158905d4, content=各位大佬们,这个杂志under editorial consideration 大概需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Thu Sep 21 14:00:28 CST 2023, time=2023-09-21, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2096624, encodeId=816c2096624f0, content=请问下大家提交后状态一直是live manuscripts代表什么呀?感觉跟大家的状态不一样呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee235490897, createdName=嘻嘻哈哈623, createdTime=Fri Oct 28 09:46:16 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147875, encodeId=5c0f214e8751c, content=请问下大家,文章proof回去之后多久能更新啊?网站上一直都还是之前我们提交的pre-proof版本, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:30:27 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2147876, encodeId=9bf2214e8765b, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:蛋白质翻译后修饰;肿瘤<br>经验分享:请问大家proof结束后多久能有排好版的文章上线啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:32:28 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2145679, encodeId=996121456e992, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤<br>经验分享:投过三次,送外审会通知你。<br>第一次外审1个月,三个审稿人,意见都不乐观,被拒。改投oncogene,中。<br>第二次外审1个月,三个审稿意见,一个乐观,2个中性,大修后接受,从投稿到接受用了4个月。<br>第三次,合作文章,并列作者,秒拒。<br>编辑的态度不错,回复问题很及时。投稿系统bug非常多!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd8b8736567, createdName=ms4000000933785288, createdTime=Fri Jun 30 16:32:39 CST 2023, time=2023-06-30, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2109990, encodeId=f6a9210999082, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤研究<br>经验分享:比较难搞,第一稿<br>Stage Start Date<br>Revision Received 2022-07-15 09:55:14<br>Waiting for Revision 2022-01-18 09:15:09<br>Decision Sent to Author 2022-01-18 09:15:09<br>Decision Pending 2022-01-18 07:43:20<br>Under Review 2021-12-15 16:40:12<br>Under Editorial Consideration 2021-12-15 10:25:39<br>Initial QC 2021-12-13 07:05:17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=482d4748397, createdName=hhhhhccc, createdTime=Thu Jan 12 20:15:37 CST 2023, time=2023-01-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2143534, encodeId=d49d21435346b, content=审稿速度:1.0<br>偏重的研究方向:肿瘤<br>经验分享:因为格式问题让修改,修改后又提交了,然后就停在Initial QC 2天了,这样不会被忘记吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Sun Jun 18 21:16:54 CST 2023, time=2023-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2128280, encodeId=dbfb212828078, content=请问这个杂质接收以后需要提交原始数据吗?提交什么格式的原始数据呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5e1735331, createdName=爱的橙子蓝, createdTime=Tue Apr 25 18:42:56 CST 2023, time=2023-04-25, status=1, ipAttribution=天津)]
    2023-06-30 ms4000000933785288 来自香港

    审稿速度:2.0 | 投稿命中率:25.0
    偏重的研究方向:肿瘤
    经验分享:投过三次,送外审会通知你。
    第一次外审1个月,三个审稿人,意见都不乐观,被拒。改投oncogene,中。
    第二次外审1个月,三个审稿意见,一个乐观,2个中性,大修后接受,从投稿到接受用了4个月。
    第三次,合作文章,并列作者,秒拒。
    编辑的态度不错,回复问题很及时。投稿系统bug非常多!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2139835, encodeId=0ab721398353a, content=偏重的研究方向:肿瘤基础研究;肿瘤<br>经验分享:审稿好慢,under editorial consideration已经五天了,这是编辑还没看吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ca15460308, createdName=ms3000001338909804, createdTime=Tue May 30 07:52:31 CST 2023, time=2023-05-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2175276, encodeId=4dec21e5276a4, content=这个期刊的under review是内审还是外审呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8332469177, createdName=12433741m11(暂无昵称), createdTime=Sat Dec 16 14:20:32 CST 2023, time=2023-12-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2158905, encodeId=9aff2158905d4, content=各位大佬们,这个杂志under editorial consideration 大概需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Thu Sep 21 14:00:28 CST 2023, time=2023-09-21, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2096624, encodeId=816c2096624f0, content=请问下大家提交后状态一直是live manuscripts代表什么呀?感觉跟大家的状态不一样呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee235490897, createdName=嘻嘻哈哈623, createdTime=Fri Oct 28 09:46:16 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147875, encodeId=5c0f214e8751c, content=请问下大家,文章proof回去之后多久能更新啊?网站上一直都还是之前我们提交的pre-proof版本, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:30:27 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2147876, encodeId=9bf2214e8765b, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:蛋白质翻译后修饰;肿瘤<br>经验分享:请问大家proof结束后多久能有排好版的文章上线啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:32:28 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2145679, encodeId=996121456e992, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤<br>经验分享:投过三次,送外审会通知你。<br>第一次外审1个月,三个审稿人,意见都不乐观,被拒。改投oncogene,中。<br>第二次外审1个月,三个审稿意见,一个乐观,2个中性,大修后接受,从投稿到接受用了4个月。<br>第三次,合作文章,并列作者,秒拒。<br>编辑的态度不错,回复问题很及时。投稿系统bug非常多!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd8b8736567, createdName=ms4000000933785288, createdTime=Fri Jun 30 16:32:39 CST 2023, time=2023-06-30, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2109990, encodeId=f6a9210999082, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤研究<br>经验分享:比较难搞,第一稿<br>Stage Start Date<br>Revision Received 2022-07-15 09:55:14<br>Waiting for Revision 2022-01-18 09:15:09<br>Decision Sent to Author 2022-01-18 09:15:09<br>Decision Pending 2022-01-18 07:43:20<br>Under Review 2021-12-15 16:40:12<br>Under Editorial Consideration 2021-12-15 10:25:39<br>Initial QC 2021-12-13 07:05:17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=482d4748397, createdName=hhhhhccc, createdTime=Thu Jan 12 20:15:37 CST 2023, time=2023-01-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2143534, encodeId=d49d21435346b, content=审稿速度:1.0<br>偏重的研究方向:肿瘤<br>经验分享:因为格式问题让修改,修改后又提交了,然后就停在Initial QC 2天了,这样不会被忘记吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Sun Jun 18 21:16:54 CST 2023, time=2023-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2128280, encodeId=dbfb212828078, content=请问这个杂质接收以后需要提交原始数据吗?提交什么格式的原始数据呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5e1735331, createdName=爱的橙子蓝, createdTime=Tue Apr 25 18:42:56 CST 2023, time=2023-04-25, status=1, ipAttribution=天津)]
    2023-01-12 hhhhhccc 来自广东省

    审稿速度:2.0 | 投稿命中率:25.0
    偏重的研究方向:肿瘤研究
    经验分享:比较难搞,第一稿
    Stage Start Date
    Revision Received 2022-07-15 09:55:14
    Waiting for Revision 2022-01-18 09:15:09
    Decision Sent to Author 2022-01-18 09:15:09
    Decision Pending 2022-01-18 07:43:20
    Under Review 2021-12-15 16:40:12
    Under Editorial Consideration 2021-12-15 10:25:39
    Initial QC 2021-12-13 07:05:17

    2

    展开2条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2139835, encodeId=0ab721398353a, content=偏重的研究方向:肿瘤基础研究;肿瘤<br>经验分享:审稿好慢,under editorial consideration已经五天了,这是编辑还没看吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ca15460308, createdName=ms3000001338909804, createdTime=Tue May 30 07:52:31 CST 2023, time=2023-05-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2175276, encodeId=4dec21e5276a4, content=这个期刊的under review是内审还是外审呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8332469177, createdName=12433741m11(暂无昵称), createdTime=Sat Dec 16 14:20:32 CST 2023, time=2023-12-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2158905, encodeId=9aff2158905d4, content=各位大佬们,这个杂志under editorial consideration 大概需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Thu Sep 21 14:00:28 CST 2023, time=2023-09-21, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2096624, encodeId=816c2096624f0, content=请问下大家提交后状态一直是live manuscripts代表什么呀?感觉跟大家的状态不一样呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee235490897, createdName=嘻嘻哈哈623, createdTime=Fri Oct 28 09:46:16 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147875, encodeId=5c0f214e8751c, content=请问下大家,文章proof回去之后多久能更新啊?网站上一直都还是之前我们提交的pre-proof版本, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:30:27 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2147876, encodeId=9bf2214e8765b, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:蛋白质翻译后修饰;肿瘤<br>经验分享:请问大家proof结束后多久能有排好版的文章上线啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:32:28 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2145679, encodeId=996121456e992, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤<br>经验分享:投过三次,送外审会通知你。<br>第一次外审1个月,三个审稿人,意见都不乐观,被拒。改投oncogene,中。<br>第二次外审1个月,三个审稿意见,一个乐观,2个中性,大修后接受,从投稿到接受用了4个月。<br>第三次,合作文章,并列作者,秒拒。<br>编辑的态度不错,回复问题很及时。投稿系统bug非常多!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd8b8736567, createdName=ms4000000933785288, createdTime=Fri Jun 30 16:32:39 CST 2023, time=2023-06-30, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2109990, encodeId=f6a9210999082, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤研究<br>经验分享:比较难搞,第一稿<br>Stage Start Date<br>Revision Received 2022-07-15 09:55:14<br>Waiting for Revision 2022-01-18 09:15:09<br>Decision Sent to Author 2022-01-18 09:15:09<br>Decision Pending 2022-01-18 07:43:20<br>Under Review 2021-12-15 16:40:12<br>Under Editorial Consideration 2021-12-15 10:25:39<br>Initial QC 2021-12-13 07:05:17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=482d4748397, createdName=hhhhhccc, createdTime=Thu Jan 12 20:15:37 CST 2023, time=2023-01-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2143534, encodeId=d49d21435346b, content=审稿速度:1.0<br>偏重的研究方向:肿瘤<br>经验分享:因为格式问题让修改,修改后又提交了,然后就停在Initial QC 2天了,这样不会被忘记吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Sun Jun 18 21:16:54 CST 2023, time=2023-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2128280, encodeId=dbfb212828078, content=请问这个杂质接收以后需要提交原始数据吗?提交什么格式的原始数据呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5e1735331, createdName=爱的橙子蓝, createdTime=Tue Apr 25 18:42:56 CST 2023, time=2023-04-25, status=1, ipAttribution=天津)]
    2023-06-18 ms2000000311873048 来自湖南省

    审稿速度:1.0
    偏重的研究方向:肿瘤
    经验分享:因为格式问题让修改,修改后又提交了,然后就停在Initial QC 2天了,这样不会被忘记吧

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2139835, encodeId=0ab721398353a, content=偏重的研究方向:肿瘤基础研究;肿瘤<br>经验分享:审稿好慢,under editorial consideration已经五天了,这是编辑还没看吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ca15460308, createdName=ms3000001338909804, createdTime=Tue May 30 07:52:31 CST 2023, time=2023-05-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2175276, encodeId=4dec21e5276a4, content=这个期刊的under review是内审还是外审呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8332469177, createdName=12433741m11(暂无昵称), createdTime=Sat Dec 16 14:20:32 CST 2023, time=2023-12-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2158905, encodeId=9aff2158905d4, content=各位大佬们,这个杂志under editorial consideration 大概需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Thu Sep 21 14:00:28 CST 2023, time=2023-09-21, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2096624, encodeId=816c2096624f0, content=请问下大家提交后状态一直是live manuscripts代表什么呀?感觉跟大家的状态不一样呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ee235490897, createdName=嘻嘻哈哈623, createdTime=Fri Oct 28 09:46:16 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147875, encodeId=5c0f214e8751c, content=请问下大家,文章proof回去之后多久能更新啊?网站上一直都还是之前我们提交的pre-proof版本, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:30:27 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2147876, encodeId=9bf2214e8765b, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:蛋白质翻译后修饰;肿瘤<br>经验分享:请问大家proof结束后多久能有排好版的文章上线啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:32:28 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2145679, encodeId=996121456e992, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤<br>经验分享:投过三次,送外审会通知你。<br>第一次外审1个月,三个审稿人,意见都不乐观,被拒。改投oncogene,中。<br>第二次外审1个月,三个审稿意见,一个乐观,2个中性,大修后接受,从投稿到接受用了4个月。<br>第三次,合作文章,并列作者,秒拒。<br>编辑的态度不错,回复问题很及时。投稿系统bug非常多!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd8b8736567, createdName=ms4000000933785288, createdTime=Fri Jun 30 16:32:39 CST 2023, time=2023-06-30, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2109990, encodeId=f6a9210999082, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤研究<br>经验分享:比较难搞,第一稿<br>Stage Start Date<br>Revision Received 2022-07-15 09:55:14<br>Waiting for Revision 2022-01-18 09:15:09<br>Decision Sent to Author 2022-01-18 09:15:09<br>Decision Pending 2022-01-18 07:43:20<br>Under Review 2021-12-15 16:40:12<br>Under Editorial Consideration 2021-12-15 10:25:39<br>Initial QC 2021-12-13 07:05:17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=482d4748397, createdName=hhhhhccc, createdTime=Thu Jan 12 20:15:37 CST 2023, time=2023-01-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2143534, encodeId=d49d21435346b, content=审稿速度:1.0<br>偏重的研究方向:肿瘤<br>经验分享:因为格式问题让修改,修改后又提交了,然后就停在Initial QC 2天了,这样不会被忘记吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Sun Jun 18 21:16:54 CST 2023, time=2023-06-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2128280, encodeId=dbfb212828078, content=请问这个杂质接收以后需要提交原始数据吗?提交什么格式的原始数据呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5e1735331, createdName=爱的橙子蓝, createdTime=Tue Apr 25 18:42:56 CST 2023, time=2023-04-25, status=1, ipAttribution=天津)]
    2023-04-25 爱的橙子蓝 来自天津

    请问这个杂质接收以后需要提交原始数据吗?提交什么格式的原始数据呀

    0

共354条页码: 1/36页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分